Диссертация (1139510), страница 51
Текст из файла (страница 51)
J Neural Transm 2005 ; 112: 1281– 96.100. Danish Universities Antidepressant Group. Paroxetine: a selective serotoninreuptake inhibitor showing better tolerance but weaker antidepressant effect thanclomipramine in a controlled multicenter study. J Affect Disord. 1990Apr;18(4):289–99101. Danish University Antidepressant Group. Citalopram: clinical effect profilein comparison with clomipramine. A controlled multicenter study.Psychopharmacology (Berl). 1986;90(1):131–8.
11.102. de Jonge P, Mangano D, Whooley MA: Differential association of cognitiveand somatic depressive symptoms with heart rate variability in patients with stablecoronary heart disease: findings from the Heart and Soul Study. Psychosom Med2007, 69:735-739.103. Dean L. Amitriptyline Therapy and CYP2D6 and CYP2C19 Genotype. 2017Mar 23. In: Pratt V, McLeod H, Rubinstein W, et al., editors. Medical GeneticsSummaries [Internet]. Bethesda (MD): National Center for BiotechnologyInformation(US);2012-. Availablefrom:https://www.ncbi.nlm.nih.gov/books/NBK425165/104. Demopulos C, Fava M, McLean NE, Alpert JE, Nierenberg AA, RosenbaumJF.
Hypochondriacal concerns in depressed outpatients. Psychosomat Med.1996;58:314-320.105. Denninger JW, Papakostas GI, Mahal Y, et al. Somatic symptoms inoutpatients with major depressive disorder treated with fluoxetine.Psychosomatics. 2006;47:348-352.106. Diagnostic and Statistical Manual of Mental Disorders (DSM–5).https://www.psychiatry.org/psychiatrists/practice/dsm107.
Donoghue J, Hylan TR. Antidepressant use in clinical practice: efficacy v.effectiveness. British Journal of Psychiatry. 2001;179(Suppl 42):9–17.108. Donoghue J, Tylee A, Wildgust H. Cross-sectional database analysis ofantidepressant prescribing in general practice in the UK, 1993–1995. BritishMedical Journal. 1996;313:861–862.276109. Donoghue J. Antidepressant use patterns in clinical practices: comparisonsamong tricyclic antidepressants and selective serotonin reuptake inhibitors. ActaPsychiatrica Scandinavica. 2000;101(Suppl 403):57–61.110. Doree JP , Des RJ , Lew V , Gendron A , Elie R , Stip E , et al . 2007 .Quetiapine augmentation of treatment-resistant depression: a comparison withlithium . Curr Med Res Opin 23 : 333 – 341 .111. Drago A, Crisafulli C, Sidoti A, Serretti A.
The molecular interactionbetween the glutamatergic, noradrenergic, dopaminergic and serotoninergicsystems informs a detailed genetic perspective on depressive phenotypes. ProgNeurobiol (2011) 94(4):418–60.112. Drago A, Ronchi DD, Serretti A Review 5-HT1A gene variants andpsychiatric disorders: a review of current literature and selection of SNPs for futurestudies. Int J Neuropsychopharmacol. 2008 Aug; 11(5):701-21.113. Durgam S, Earley W, Guo H, Li D, Nemeth G, Laszlovszky I et al. Efficacyand safety of adjunctive cariprazine in inadequate responders to antidepressants: arandomized, double-blind, placebo-controlled study in adult patients with majordepressive disorder.
J Clin Psychiatry 2016; 77: 371–378.114. Eaton WW, Shao H, Nestadt G et al. Population-based study of first onsetand chronicity in major depressive disorder. Arch Gen Psychiatry 2008;65:513–20.115. Elhai JD, Naifeh JA, Forbes D, Ractliffe KC, Tamburrino M: Heterogeneityin clinical presentations of posttraumatic stress disorder among medical patients:testing factor structure variation using factor mixture modeling. J Trauma Stress2011, 24:435-443.116. El-Khalili N , Joyce M , Atkinson S , Buynak RJ , Datto C , Lindgren P , etal .
2010 . Extended-release quetiapine fumarate (quetiapine XR) as adjunctivetherapy in major depressive disorder (MDD) in patients with an inadequateresponse to ongoing antidepressant treatment: a multicentre, randomized, doubleblind, placebo-controlled study . Int J Neuropsychopharmacol 13 : 917 – 932117.
Eyal S, Ke B, Muzi M, Link JM, Mankoff DA, Collier AC et al. Regional Pglycoprotein activity and inhibition at the human blood–brain barrier as imaged bypositron emission tomography. Clin Pharmacol Ther 2010; 87: 579–585.118. Fava G.A.
Road to nowhere // World Psychiatry. 2014. Vol 13. P. 49.119. Fava M , Mischoulon D , Iosifescu D , Witte J , Pencina M , Flynn M , et al .2012 . A double-blind, placebo-controlled study of aripiprazole adjunctive toantidepressant therapy among depressed outpatients with inadequate response toprior antidepressant therapy (ADAPT-A Study) . Psychother Psychosom 81 : 87 –97 .277120. Fava M, Abraham M, Alpert J, et al.
Gender differences in Axis Icomorbidity among depressed outpatients. J Affect Disord. 1996;38:129-133.121. Fava M, Borus JS, Alpert JE, Nierenberg AA, Rosenbaum JF, Bottiglieri T.Folate, vitamin B12, and homocysteine in major depressive disorder. Am JPsychiatry. 1997;154:426-428.122. Fava M, Bouffides E, Pava JA, McCarthy MK, Steingard RJ, Rosenbaum JF.Personality disorder comorbidity with major depression and response to fluoxetinetreatment. Psychother Psychosom. 1994;62:160-167.123. Fava M, Hoog SL, Judge RA, Kopp JB, Nilsson ME, Gonzales JS. Acuteefficacy of fluoxetine versus sertraline and paroxetine in major depressive disorderincluding effects of baseline insomnia. J Clin Psychopharmacol.
2002;22:137-147.124. Fava M, Labbate LA, Abraham ME, Rosenbaum JF. Hypothyroidism andhyperthyroidism in major depression revisited. J Clin Psychiatry. 1995;56:186192.125. Fava M, Uebelacker LA, Alpert JE, Nierenberg AA, Pava JA, RosenbaumJF. Major depressive subtypes and treatment response. Biol Psychiatry.1997;42:568-576.126. Feng Y, Wigg KG, Makkar R, Ickowicz A, Pathare T, Tannock R, RobertsW, Malone M, Kennedy JL, Schachar R, Barr CL. Sequence variation in the 3'untranslated region of the dopamine transporter gene and attention-deficithyperactivity disorder (ADHD).
Am J Med Genet B Neuropsychiatr Genet. 2005Nov 5; 139B(1):1-6.127. Ferrari AJ, Charlson FJ, Norman RE, Flaxman AD, Patten SB, Vos T,Whiteford HA. The epidemiological modelling of major depressive disorder:application for the Global Burden of Disease Study 2010. PLoS One. 2013 Jul29;8(7):e69637128.
Ferrari AJ, Charlson FJ, Norman RE, Patten SB, Freedman G, Murray CJ,Vos T, Whiteford HA. Burden of depressive disorders by country, sex, age, andyear: findings from the global burden of disease study 2010. PLoS Med. 2013Nov;10(11):e1001547.129. Fischer, A. G., Jocham, G., and Ullsperger, M.
(2014). Dual serotonergicsignals: a key to understanding paradoxical effects? Trends Cogn. Sci. 2014 Dec10. pii: S1364-6613(14)00237-X.130. Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug effects anddepression severity: a patient-level meta-analysis. JAMA.
2010;303(1):47-53.131. Frances A. RDoC is necessary, but very oversold // World Psychiatry. 2014.Vol. 13. P. 48–49.278132. Freedman R , Lewis DA , Michels R , Pine DS , Schultz SK , Tamminga CA, et al . 2013 . The initial field trials of DSM-5: new blooms and old thorns.
Am JPsychiatry 170: 1–5.133. Fried EI, Epskamp S, Nesse RM et al. What are ‘good’ depressionsymptoms? Comparing the centrality of DSM and non-DSM symptoms ofdepression in a network analysis. J Affect Disord 2016;189: 314-20.134. Fried EI, Nesse RM et al. Depression is more than the sum-score of its parts:individual DSM symptoms have different risk factors.
Psychol Med. 2014 July ;44(10): 2067–2076.135. Fried EI, Nesse RM. Depression sum-scores don’t add up: why analyzingspecific depression symptoms is essential. BMC Med. 2015;13:1–11.136. Fried EI, van Borkulo CD, Epskamp S, et al. Measuring depression overtime or not? Lack of unidimensionality and longitudinal measurement invariancein four common rating scales of depression. Psychol Assess. 2016;28:1354–1367.137. Fried EI. Moving forward: how depression heterogeneity hinders progress intreatment and research. Expert Review Of Neurotherapeutics, 2017 vol.
17, no. 5,423–425138. Fried EI. Problematic assumptions have slowed down depression research:why symptoms, not syndromes are the way forward. Front Psychol. 2015 Mar23;6:309.139. Friedman, RA, Parides, M, Baff, R, Moran, M, Kocsis, JH. Predictors ofresponse to desipramine in dysthymia. J Clin Psychopharmacol.
1995;15:280- 283.140. Gaikovitch EA, Cascorbi I, Mrozikiewicz PM, Brockmöller J, Frötschl R,Köpke K, Gerloff T, Chernov JN, Roots I. Polymorphisms of drug-metabolizingenzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein ina Russian population. Eur J Clin Pharmacol. 2003 Aug;59(4):303-12.141. Geddes JR, Carney SM, Davies C et al. Relapse prevention withantidepressant drug treatment in depressive disorders: a systematicreview. Lancet 2003;361:653–61.142. Ghaemi SN, Vöhringer PA. The heterogeneity of depression: an old debaterenewed. Acta Psychiatr Scand. 2011 Dec;124(6):497.143.
Gibbons RD, Hur K, Brown CH, Davis JM, Mann JJ. Benefits fromantidepressants: synthesis of 6-week patient-level outcomes from double-blindplacebo-controlled randomized trials of fluoxetine and venlafaxine. Arch GenPsychiatry 2012; 69:572–579.144. Goshen I, Kreisel T, Ounallah-Saad H, Renbaum P, Zalzstein Y, Ben-Hur T,et al. A dual role for interleukin-1 in hippocampal-dependent memory processes.Psychoneuroendocrinology. 2007;32:1106–1115.279145. Greden JF. The Burden of Recurrent Depression: Causes, Consequences, andFuture Prospects.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
